Amphastar Pharma Stock (NASDAQ:AMPH), Trade Ideas

Amphastar Pharma

Amphastar Pharmaceuticals Inc is a biopharmaceutical company that focuses on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the company sells insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has two reportable segments finished pharmaceutical products and API products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.

AMPH

Analyst Color

Biotech

News

Health Care

Analyst Ratings

Trading Ideas

General

Amphastar Pharmaceuticals discusses the future of Baqsimi at the Needham Healthcare Conference, highlighting its potential amid a growing market for glucagon products. With promising sales projections and strategic initiatives, Amphastar aims to capitalize on emerging opportunities in the endocrinology sector for continued growth.

Amphastar Pharmaceuticals Interested In Potential Acquisitions In Endocrinology-Focused Companies

What Vitamins Did For Healthy Living, Stemtech Corporation (OTCQB: STEK) Says It Is Doing For Anti-Aging With Stem Cell Nutrition

Penny Stocks

Small Cap

HSIC

NATR

STEK

Vitamins may not be a miracle cure, but combined with exercise and a healthy diet, they have the potential to greatly improve health and wellness. It’s no wonder vitamin supplements are a multi-billion dollar business, projected to hit a market size of $98 billion in less than a decade.

Long Ideas

Markets

Media

BNTX

MRNA

PAAS

STWD

On CNBC’s &#34;Mad Money Lightning Round,&#34; Jim Cramer said he would back  Moderna, Inc.  (NASDAQ: MRNA) here.

Jim Cramer Says Hold Onto This Biotech Stock: &#39;I Don&#39;t Understand Why It&#39;s So Inexpensive&#39;

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharmaceuticals Inc

Amphenol Corp

Amphitrite Digital Inc

At the Needham Healthcare Conference,&nbsp;Amphastar Pharmaceuticals Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) highlighted why they remain excited about Baqsimi, the inhaled glucagon&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/23/04/31954035/eli-lilly-divests-low-blood-sugar-drug-baqsimi-to-amphastar-for-500m-cash" rel="noreferrer noopener">product for severe hypoglycemia</a>.&nbsp;
Amphastar Pharmaceuticals develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products.
Needham&nbsp;says the company still believes Baqsimi is the best glucagon product based on its expertise, which is difficult to genericize, and its IP that goes to 2036.
Needham notes that the market opportunity for Baqsimi is promising because only a small fraction of insulin users currently receive a prescription for glucagon to manage emergency hypoglycemia.&nbsp;
There&#8217;s a widespread recommendation among doctors and guidelines that all insulin users should have access to a glucagon product, akin to an Epipen, for diabetic emergencies.&nbsp;
Baqsimi is projected to reach peak sales of $250-270 million, a significant increase from $153 million in 2023.&nbsp;
These sales estimates might be conservative, especially if the market expands, as Baqsimi currently faces competition primarily from Gvoke, another injectable glucagon product.
In 2024, Amphastar Pharmaceuticals anticipates Baqsimi&#8217;s inaugural full-year performance to be fueled by a modest increase in product units sold, coupled with a slight decrease in prices due to elevated wholesaler fees compared to those paid by&nbsp;Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>).
In anticipation of competitors re-entering the market by the second half of 2024 and 2025, Amphastar Pharmaceuticals foresees new opportunities emerging despite potential shortages.&nbsp;
Amphastar Pharmaceuticals is keen on exploring business development prospects, particularly in the endocrinology sector, to expand its product portfolio by leveraging Baqsimi&#8217;s commercial infrastructure. With $300 million in cash reserves and strong cash flow, Amphastar Pharmaceuticals is inclined towards debt financing for potential asset acquisitions.
Needham&nbsp;<a target="_blank" href="https://www.benzinga.com/quote/AMPH/analyst-ratings" rel="noreferrer noopener">keeps the Hold rating</a>&nbsp;for Amphastar Pharmaceuticals.
Price Action:&nbsp;AMPH shares are down 2.33% at $39.95 on the last check Wednesday.

Needham analyst Serge Belanger reiterates Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) with a Hold.

Reiteration

Needham Reiterates Hold on Amphastar Pharma

JP Morgan analyst Ekaterina Knyazkova initiates coverage on Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) with a Overweight rating and announces Price Target of $60.

Price Target

Initiation

JP Morgan Initiates Coverage On Amphastar Pharma with Overweight Rating, Announces Price Target of $60

WIIM

Amphastar Pharmaceuticals shares are trading lower after the company reported mixed Q4 financial results.

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) reported quarterly earnings of $0.88 per share which missed the analyst consensus estimate of $0.91 by 3.3 percent. This is a 20.55 percent increase over earnings of $0.73 per share from the same period last year. The company reported quarterly sales of $178.10 million which beat the analyst consensus estimate of $175.67 million by 1.39 percent. This is a 31.91 percent increase over sales of $135.02 million the same period last year.

Earnings

Amphastar Pharma Q4 EPS $0.88 Misses $0.91 Estimate, Sales $178.10M Beat $175.67M Estimate

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-02-28. Here's what investors need to know before the announcement.
Analysts estimate that Amphastar Pharma will report an earnings per share (EPS) of $0.91. 
Amphastar Pharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.46, which was followed by a 15.39% increase in the share price the next day.
Here's a look at Amphastar Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.69</td>
<td>0.56</td>
<td>0.48</td>
<td>0.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.15</td>
<td>0.65</td>
<td>0.62</td>
<td>0.73</td>
</tr>
<tr>
<td>Price Change %</td>
<td>15.0%</td>
<td>-4.0%</td>
<td>13.0%</td>
<td>15.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1709046100_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Amphastar Pharma were trading at $55.09 as of February 26. Over the last 52-week period, shares are up 52.63%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/AMPH/earnings">To track all earnings releases for Amphastar Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Amphastar Pharma

RICHARD PRINS, Board Member at Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>), reported a large insider sell on November 20, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001297184/000110465923119974//Archives/edgar/data/1297184/000110465923119974/0001104659-23-119974-index.htm">U.S. Securities and Exchange Commission</a> on Monday showed that PRINS sold 4,000 shares of Amphastar Pharma. The total transaction amounted to $223,445. 
Amphastar Pharma shares are trading up 1.25% at $57.3 at the time of this writing on Tuesday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001297184">Check Out The Full List Of Amphastar Pharma's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Amphastar Pharma Insider Trades Send a Signal

B of A Securities analyst Jason Gerberry initiates coverage on Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) with a Neutral rating and announces Price Target of $63.

B of A Securities Initiates Coverage On Amphastar Pharma with Neutral Rating, Announces Price Target of $63

Amphastar Pharmaceuticals shares are trading higher after the company reported better-than-expected Q3 financial results.

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) reported quarterly Adj earnings of $1.15 per share which beat the analyst consensus estimate of $0.69 by 66.67 percent. This is a 202.63 percent increase over earnings of $0.38 per share from the same period last year. The company reported quarterly sales of $180.56 million which beat the analyst consensus estimate of $174.63 million by 3.39 percent. This is a 50.30 percent increase over sales of $120.13 million the same period last year.

Amphastar Pharma Q3 Adj EPS $1.15 Beats $0.69 Estimate, Sales $180.56M Beat $174.63M Estimate

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) reported its Q3 earnings results on Wednesday, November 8, 2023 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Amphastar Pharma beat estimated earnings by 66.67%, reporting an EPS of $1.15 versus an estimate of $0.69.
Revenue was up $60.43 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.09 which was followed by a 4.29% drop in the share price the next day.
Here's a look at Amphastar Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.56</td>
<td>0.48</td>
<td>0.41</td>
<td>0.39</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.65</td>
<td>0.62</td>
<td>0.73</td>
<td>0.38</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>137.37M</td>
<td>136.33M</td>
<td>126.98M</td>
<td>126.37M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>145.71M</td>
<td>140.02M</td>
<td>135.02M</td>
<td>120.13M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Amphastar Pharma <a href="https://www.benzinga.com/quote/AMPH/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Amphastar Pharma Q3 Earnings

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) is set to give its latest quarterly earnings report on Wednesday, 2023-11-08. Here's what investors need to know before the announcement.
Analysts estimate that Amphastar Pharma will report an earnings per share (EPS) of $0.69. 
Amphastar Pharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.09, which was followed by a 4.29% drop in the share price the next day.
Here's a look at Amphastar Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
<th>Q3 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.56</td>
<td>0.48</td>
<td>0.41</td>
<td>0.39</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.65</td>
<td>0.62</td>
<td>0.73</td>
<td>0.38</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-4.29%</td>
<td>13.04%</td>
<td>14.75%</td>
<td>-9.37%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2023/1699365704_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Amphastar Pharma were trading at $46.83 as of November 03. Over the last 52-week period, shares are up 65.71%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/AMPH/earnings">To track all earnings releases for Amphastar Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Amphastar Pharma

Amphastar Pharmaceuticals Prices Offering Of $300M Of 2.00% Convertible Senior Notes Due 2029

<h3>Gainers</h3>
<ul>
<li>MoonLake (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLTX#NASDAQ">MLTX</a>) shares rose 18.8% to $62.5 during Monday's after-market session. Today's trading volume for this security ended up closing at 260.5K shares, which is 35.3 percent of its average volume over the last 100 days. The market value of their outstanding shares is at $3.3 billion. </li>
<li>Renalytix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNLX#NASDAQ">RNLX</a>) stock moved upwards by 14.86% to $2.55. The company's market cap stands at $121.1 million. </li>
<li>Jasper Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JSPR#NASDAQ">JSPR</a>) shares rose 9.06% to $0.84. The company's market cap stands at $93.0 million. </li>
<li>Virpax Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRPX#NASDAQ">VRPX</a>) stock moved upwards by 7.87% to $0.85. The market value of their outstanding shares is at $9.9 million. </li>
<li>Biophytis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BPTS#NASDAQ">BPTS</a>) stock moved upwards by 7.69% to $1.54. The market value of their outstanding shares is at $8.2 million. </li>
<li>MSP Recovery (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIFW#NASDAQ">LIFW</a>) shares increased by 7.62% to $0.06. This security traded at a volume of 167.8K shares come close, making up 15.8% of its average volume over the last 100 days. The company's market cap stands at $21.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Sight Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGHT#NASDAQ">SGHT</a>) shares decreased by 25.0% to $4.88 during Monday's after-market session. The market value of their outstanding shares is at $237.4 million. </li>
<li>Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) shares declined by 11.91% to $1.11. The company's market cap stands at $18.0 million. </li>
<li>Nemaura Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMRD#NASDAQ">NMRD</a>) stock fell 8.13% to $0.37. The market value of their outstanding shares is at $10.6 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock decreased by 7.02% to $0.53. The company's market cap stands at $3.4 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares fell 6.85% to $0.35. The company's market cap stands at $4.0 million. </li>
<li>Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) stock declined by 6.57% to $48.0. The market value of their outstanding shares is at $2.3 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

APVO

BPTS

ELUT

Jasper Therapeutics, Inc. - Class A Common Stock

JSPR

LIFW

MLTX

NMRD

RNLX

SGHT

VRPX

VTAK

12 Health Care Stocks Moving In Monday's After-Market Session

RICHARD PRINS, Board Member at Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>), reported a large insider sell on August 21, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001297184/000110465923093905//Archives/edgar/data/1297184/000110465923093905/0001104659-23-093905-index.htm">U.S. Securities and Exchange Commission</a> on Monday showed that PRINS sold 2,000 shares of Amphastar Pharma. The total transaction amounted to $105,005. 
Amphastar Pharma shares are trading down 0.97% at $52.96 at the time of this writing on Tuesday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001297184">Check Out The Full List Of Amphastar Pharma's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Board Member At This Health Care Company Sells $105K of Stock

RICHARD PRINS, Board Member at Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>), reported a large insider sell on August 17, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001297184/000110465923092758//Archives/edgar/data/1297184/000110465923092758/0001104659-23-092758-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that PRINS sold 4,163 shares of Amphastar Pharma. The total transaction amounted to $238,911. 
Amphastar Pharma shares are trading down 2.6% at $54.59 at the time of this writing on Thursday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Important Transaction Codes</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001297184">Check Out The Full List Of Amphastar Pharma's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Amphastar Pharma Recent Insider Activity

MICHAEL ZASLOFF, Board Member at Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>), reported a large insider sell on August 17, according to a new SEC filing. 
What Happened: A Form 4 filing from the <a href="https://www.sec.gov/Archives/edgar/data/0001297184/000110465923092759//Archives/edgar/data/1297184/000110465923092759/0001104659-23-092759-index.htm">U.S. Securities and Exchange Commission</a> on Thursday showed that ZASLOFF sold 12,759 shares of Amphastar Pharma. The total transaction amounted to $730,025. 
Amphastar Pharma shares are trading down 2.6% at $54.59 at the time of this writing on Thursday morning.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however an insider transaction can be an important factor in the investing decision. 
In legal terms, an "insider" refers to any shareholder who owns at least 10% of a company. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Transaction Codes To Focus On</h3>
<a href="https://www.benzinga.com/money/investing-tools">Investors</a> prefer focusing on transactions that take place in the open market, indicated in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S indicates a sale. Transaction code C indicates the conversion of an option, and transaction code A indicates the insider may have been forced to sell shares in order to receive compensation that had been promised upon being hired by the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001297184">Check Out The Full List Of Amphastar Pharma's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Board Member of Amphastar Pharma Sold $730K In Stock

Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) reported quarterly earnings of $0.65 per share which beat the analyst consensus estimate of $0.56 by 16.07 percent. This is a 66.67 percent increase over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $145.71 million which beat the analyst consensus estimate of $137.37 million by 6.07 percent. This is a 18.02 percent increase over sales of $123.47 million the same period last year.

Amphastar Pharma Q2Adj  EPS $0.65 Beats $0.56 Estimate, Sales $145.71M Beat $137.37M Estimate

Jefferies analyst Glen Santangelo reinstates Amphastar Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMPH#NASDAQ">AMPH</a>) with a Buy and announces $70 price target.

Jefferies Reinstates Buy on Amphastar Pharma, Announces $70 Price Target

Thursday, February 29, 2024 - Amphastar Pharma (AMPH) reported downside earnings and upside revenues.The consensus among analysts for Amphastar Pharma was for an earnings per share (EPS) of $0.91. The firm failed to meet those projections, reporting an EPS of $0.88, a negative surprise of $0.03 (-3%). Profits rose 21% year

Amphastar Pharma Down 13.24% To $47.49 After Earnings Miss

Amphastar Pharmaceuticals, Inc. (AMPH) Q4 2023 Earnings Call Transcript

Why Amphastar Pharmaceuticals Is A Strong Buy: Growth, Valuation, And Strategic Acquisitions

The 65 rating InvestorsObserver gives to Amphastar Pharmaceuticals Inc (AMPH)  stock puts it near the top of the Drug Manufacturers - Specialty and Generic industry. In addition to scoring higher than 88 percent of stocks in the Drug Manufacturers - Specialty and Generic industry, AMPHâ€&#x2122;s 65 overall rating means the stock s

Where Does Amphastar Pharmaceuticals Inc (AMPH) Stock Fall in the Drug Manufacturers - Specialty & Generic Field After It Has Fallen -15.84% This Week?

Amphastar a new overweight at J.P. Morgan on diverse asset portfolio

Teva upgraded at J.P. Morgan on upcoming catalysts

By 2031, U.S. healthcare spending is projected to surpass $7 trillion, accounting for almost 20% of U.S. GDP. As the demand for more affordable opt...

Amphastar Pharmaceuticals (NASDAQ:AMPH) Offers Savvy Value Investors a Window of Opportunity

Needham analyst Serge Belanger maintained a Hold rating on Amphastar Pharmaceuticals (AMPH – Research Report) today. The company's shares closed ye...

Needham Sticks to Its Hold Rating for Amphastar Pharmaceuticals (AMPH)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amphastar Pharmaceuticals (AMPH – Research Report), Ascendis Phar...

Analysts Have Conflicting Sentiments on These Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Ascendis Pharma (ASND) and AMN Healthcare Services (AMN)

Analyst Tim Chiang of Capital One Financial maintained a Buy rating on Amphastar Pharmaceuticals (AMPH – Research Report), retaining the price targ...